Get the Stockscreener App
80.47
2.13%
-1.75
After Hours:
80.47
Nuvalent Inc stock is traded at $80.47, with a volume of 403.73K.
It is down -2.13% in the last 24 hours and up +5.04% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$82.22
Open:
$81.99
24h Volume:
403.73K
Relative Volume:
0.82
Market Cap:
$5.36B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-20.63
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-0.52%
1M Performance:
+5.04%
6M Performance:
+10.96%
1Y Performance:
-1.48%
1-Day Range:
$80.13
$82.40
1-Week Range:
$74.40
$83.09
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
80.47 | 5.66B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent, Inc. $NUVL Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Fred Alger Management LLC Reduces Stock Position in Nuvalent, Inc. $NUVL - MarketBeat
Wedbush Reaffirms "Outperform" Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Voleon Capital Management LP Invests $1.49 Million in Nuvalent, Inc. $NUVL - MarketBeat
Alyeska Investment Group L.P. Decreases Stock Position in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent, Inc. $NUVL Stake Cut by Adage Capital Partners GP L.L.C. - MarketBeat
Nuvalent (NASDAQ:NUVL) Coverage Initiated at Guggenheim - MarketBeat
Nuvalent, Inc. $NUVL Shares Purchased by Parkman Healthcare Partners LLC - MarketBeat
What makes Nuvalent Inc. stock attractive todayJuly 2025 Volume & Real-Time Volume Trigger Notifications - Lancaster City Council
Can Nuvalent Inc. grow without external fundingLong Setup & Daily Growth Stock Investment Tips - Lancaster City Council
Drawdown in Nuvalent Inc. May Be Nearing End2025 Analyst Calls & Stock Timing and Entry Methods - beatles.ru
Harpreet Singh Showcases Biotech on the Main Stage at WCLC2025 - Oncodaily
Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts - MSN
Walleye Capital LLC Sells 42,253 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 - StreetInsider
Breaking Lung Cancer Treatment Advance: Nuvalent's Zidesamtinib Shows Promise in Critical NSCLC Trial - Stock Titan
Nuvalent Inc. Sees Spike in Bullish Option FlowJuly 2025 Catalysts & Free Weekly Chart Analysis and Trade Guides - beatles.ru
Nuvalent, Inc. $NUVL is Vestal Point Capital LP's 4th Largest Position - MarketBeat
Is it too late to sell Nuvalent Inc.July 2025 Update & AI Forecast Swing Trade Picks - Newser
Can momentum traders help lift Nuvalent Inc.2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
When is the best time to exit Nuvalent Inc.Portfolio Update Report & Advanced Swing Trade Entry Alerts - Newser
Braidwell LP Has $59.64 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Is Nuvalent Inc. stock forming a triangle pattern2025 Market Overview & Verified Technical Trade Signals - خودرو بانک
Is now the right time to enter Nuvalent Inc.Quarterly Performance Summary & Technical Confirmation Trade Alerts - خودرو بانک
Market reaction to Nuvalent Inc.’s recent newsWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Is Nuvalent Inc. stock a buy or sellTreasury Yields & Weekly Watchlist for Hot Stocks - خودرو بانک
Best data tools to analyze Nuvalent Inc. stockJuly 2025 Update & Daily Entry Point Alerts - Newser
Is Nuvalent Inc.’s ROIC above industry averageJuly 2025 Big Picture & Safe Swing Trade Setups - خودرو بانک
Nuvalent, Inc. $NUVL Holdings Trimmed by Northern Trust Corp - MarketBeat
Should I buy Nuvalent Inc. stock now2025 Institutional Moves & Low Risk High Reward Ideas - خودرو بانک
Can Nuvalent Inc. navigate macro headwindsInflation Watch & Verified Short-Term Plans - 더경남뉴스
Inflation Data: Can Nuvalent Inc. navigate macro headwindsJuly 2025 Analyst Calls & Free Real-Time Market Sentiment Alerts - khodrobank.com
Nuvalent, Inc. $NUVL is Paradigm Biocapital Advisors LP's Largest Position - MarketBeat
How moving averages guide Nuvalent Inc. tradingQuarterly Earnings Summary & Verified Momentum Stock Ideas - Newser
Is Nuvalent Inc. stock entering bullish territory2025 Valuation Update & Daily Chart Pattern Signal Reports - Newser
Nuvalent Inc. stock outlook for YEARMarket Trend Review & High Conviction Buy Zone Alerts - Newser
BostInnoCoconut water out, cactus water in | Nuvalent's $166M Nasdaq debut - The Business Journals
Can Nuvalent Inc. continue delivering strong returnsQuarterly Portfolio Report & Safe Capital Investment Plans - خودرو بانک
Guggenheim initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com Canada
Guggenheim initiates coverage on Nuvalent stock with Buy rating - Investing.com
How is Nuvalent Inc. managing supply chain issuesWeekly Stock Summary & Accurate Trade Setup Notifications - خودرو بانک
Can Nuvalent Inc. rally from current levelsIndex Update & AI Driven Stock Reports - Newser
Momentum divergence signals in Nuvalent Inc. chart2025 Market Outlook & Daily Stock Momentum Reports - Newser
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):